Autologous dermal flap techniques beyond inferior dermal flap coverage in implant-based breast reconstruction: A systematic review.

Eur J Surg OncolAug 11, 2026 (epub)
Clinical ResearchPlastic SurgeryOncology (Medical)

Adam Boukind, Nicholas C Speller, Amy Liao et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

While inferior dermal flap (IDF) techniques are gaining popularity for implant-based reconstruction (IBBR), a range of autologous dermal flap (ADF) modifications have been described that serve purposes beyond standard implant coverage.

Reported results

Out of 15,678 initial articles, 17 met the inclusion criteria encompassing 357 patients and 535 breasts across 12 retrospective studies, 3 case reports, 1 prospective case series, and 1 randomized controlled trial. Techniques identified included nipple-carrying autologous dermal flaps using various pedicle configurations, meshed autologous dermis, skin-island carrying flaps, contralateral dermal grafting, autodermal…

Authors' conclusions

This review identifies and categorizes a spectrum of autologous dermal flap modifications beyond standard inferior dermal flap coverage, demonstrating that broader pedicle configurations are consistently associated with reduced NAC necrosis rates.

Source

PubMed · PMID 42594494

Published in Eur J Surg Oncol. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.